1-1 of 1
on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC)
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Clinical Trials & Observations
Bronno van der Holt, Bob Löwenberg, Alan K. Burnett, Wolfgang U. Knauf, John Shepherd, Pier Paolo Piccaluga, Gert J. Ossenkoppele, Gregor E. G. Verhoef, Augustin Ferrant, Michael Crump, Dominik Selleslag, Matthias Theobald, Martin F. Fey, Edo Vellenga, Margaret Dugan, Pieter Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC)
Journal: Blood
Blood (2005) 106 (8): 2646–2654.
https://doi.org/10.1182/blood-2005-04-1395
Published: 2005